Cargando…
Pharmacophore and 3D-QSAR Characterization of 6-Arylquinazolin-4-amines as Cdc2-like Kinase 4 (Clk4) and Dual Specificity Tyrosine-phosphorylation-regulated Kinase 1A (Dyrk1A) Inhibitors
[Image: see text] Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) are protein kinases that are promising targets for treatment of diseases caused by abnormal gene splicing. 6-Arylquinazolin-4-amines have been recently identified as potent Clk4 and...
Autores principales: | Pan, Yongmei, Wang, Yanli, Bryant, Stephen H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2013
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633254/ https://www.ncbi.nlm.nih.gov/pubmed/23496085 http://dx.doi.org/10.1021/ci300625c |
Ejemplares similares
-
SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4
por: Tiek, Deanna, et al.
Publicado: (2023) -
Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer
por: Corr, Bradley R, et al.
Publicado: (2023) -
Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimer’s Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme
por: Leal, Felipe Dias, et al.
Publicado: (2015) -
Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning
por: Al-Tawil, Mai Fayiz, et al.
Publicado: (2022) -
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
por: Lindberg, Mattias F., et al.
Publicado: (2021)